Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Lipocine reports Q2 EPS (13c), consensus (7c) » 08:56
08/06/20
08/06
08:56
08/06/20
08:56
LPCN

Lipocine

$1.95 /

+0.1 (+5.41%)

Lipocine said, "As…

Lipocine said, "As of June 30, 2020, we had $18.3 million of unrestricted cash, cash equivalents and marketable investment securities compared to $14.1 million at December 31, 2019. Additionally, as of June 30, 2020 and December 31, 2019 we had $5.0 million of restricted cash, which is required to be maintained as cash collateral under the SVB Loan and Security Agreement until TLANDO is approved by the FDA."

ShowHide Related Items >><<
LPCN Lipocine
$1.95 /

+0.1 (+5.41%)

LPCN Lipocine
$1.95 /

+0.1 (+5.41%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
  • 14
    Nov
LPCN Lipocine
$1.95 /

+0.1 (+5.41%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
08/05/20
08/05
08:45
08/05/20
08:45
DGLY

Digital Ally

$3.35 /

+0.12 (+3.72%)

, BPY

Brookfield Property

$11.55 /

+0.23 (+2.03%)

, BLDP

Ballard Power

$15.02 /

-0.3 (-1.96%)

, LPCN

Lipocine

$1.85 /

+0.14 (+8.19%)

, CEQP

Crestwood Equity

$15.58 /

+0.625 (+4.18%)

, BLNK

Blink Charging

$11.35 /

+0.82 (+7.79%)

, AYRO

AYRO

$4.46 /

-0.115 (-2.51%)

, NBL

Noble Energy

$10.19 /

+0.23 (+2.31%)

, MAC

Macerich

$8.14 /

+0.53 (+6.97%)

, NBRV

Nabriva Therapeutics

$0.80 /

+0.0307 (+3.98%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Digital Ally (DGLY) 53.54% +5.63, Brookfield Property (BPY) 19.20% +4.54, Ballard Power (BLDP) 12.08% +3.22, Lipocine (LPCN) 16.88% +2.79, Crestwood Equity (CEQP) 16.96% +1.79, Blink Charging (BLNK) 72.75% +1.22, AYRO (AYRO) 101.43% +0.90, Noble Energy (NBL) 0.78% +0.43, Macerich (MAC) 10.45% +0.37, and Nabriva Therapeutics (NBRV) 32.82% +0.29.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$0.80 /

+0.0307 (+3.98%)

NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

MAC Macerich
$8.14 /

+0.53 (+6.97%)

LPCN Lipocine
$1.85 /

+0.14 (+8.19%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

CEQP Crestwood Equity
$15.58 /

+0.625 (+4.18%)

BPY Brookfield Property
$11.55 /

+0.23 (+2.03%)

BLNK Blink Charging
$11.35 /

+0.82 (+7.79%)

BLDP Ballard Power
$15.02 /

-0.3 (-1.96%)

AYRO AYRO
$4.46 /

-0.115 (-2.51%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

06/29/20 Aegis
Digital Ally initiated with a Buy at Aegis
BPY Brookfield Property
$11.55 /

+0.23 (+2.03%)

03/26/20 RBC Capital
Cheesecake, AMC news highlight tenants financial stress, says RBC Capital
12/18/19 Canaccord
Brookfield Property downgraded to Hold from Buy at Canaccord
08/07/19
Fly Intel: Top five analyst initiations
08/07/19 CIBC
Brookfield Property initiated with an Outperformer at CIBC
BLDP Ballard Power
$15.02 /

-0.3 (-1.96%)

07/13/20 Roth Capital
Ballard Power price target raised to $25 from $20 at Roth Capital
07/06/20 National Bank
Ballard Power initiated with a Sector Perform at National Bank
06/29/20 Roth Capital
Ballard Power upgraded to Buy at Roth Capital
06/29/20 Roth Capital
Ballard Power upgraded to Buy from Neutral at Roth Capital
LPCN Lipocine
$1.85 /

+0.14 (+8.19%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
CEQP Crestwood Equity
$15.58 /

+0.625 (+4.18%)

07/22/20 Wells Fargo
Crestwood Equity downgraded to Underweight at Wells Fargo
07/22/20 Wells Fargo
Crestwood Equity downgraded to Underweight from Equal Weight at Wells Fargo
05/13/20 Truist
Crestwood Equity price target raised to $12 from $8 at SunTrust
05/12/20 Wells Fargo
Crestwood Equity downgraded to Equal Weight from Overweight at Wells Fargo
BLNK Blink Charging
$11.35 /

+0.82 (+7.79%)

08/26/19 ThinkEquity
Blink Charging initiated with a Buy at ThinkEquity
AYRO AYRO
$4.46 /

-0.115 (-2.51%)

NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

08/04/20 Truist
Noble Energy downgraded to Hold from Buy at Truist
08/03/20 Stifel
Noble Energy downgraded to Hold from Buy at Stifel
07/22/20 Argus
Noble Energy downgraded to Sell from Hold at Argus
07/21/20
Fly Intel: Top five analyst downgrades
MAC Macerich
$8.14 /

+0.53 (+6.97%)

07/27/20 Deutsche Bank
Macerich price target lowered to $8 from $16 at Deutsche Bank
07/02/20 Citi
Macerich price target raised to $8 from $5 at Citi
07/01/20 Goldman Sachs
Macerich resumed with a Sell at Goldman Sachs
06/18/20 JPMorgan
Macerich price target lowered to $11 from $30 at JPMorgan
NBRV Nabriva Therapeutics
$0.80 /

+0.0307 (+3.98%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
NBRV Nabriva Therapeutics
$0.80 /

+0.0307 (+3.98%)

NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

MAC Macerich
$8.14 /

+0.53 (+6.97%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

CEQP Crestwood Equity
$15.58 /

+0.625 (+4.18%)

BLDP Ballard Power
$15.02 /

-0.3 (-1.96%)

  • 08
    Jun
  • 02
    Jun
  • 28
    Feb
  • 14
    Nov
NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

BPY Brookfield Property
$11.55 /

+0.23 (+2.03%)

BLDP Ballard Power
$15.02 /

-0.3 (-1.96%)

NBRV Nabriva Therapeutics
$0.80 /

+0.0307 (+3.98%)

NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

BLNK Blink Charging
$11.35 /

+0.82 (+7.79%)

MAC Macerich
$8.14 /

+0.53 (+6.97%)

NBRV Nabriva Therapeutics
$0.80 /

+0.0307 (+3.98%)

NBL Noble Energy
$10.19 /

+0.23 (+2.31%)

MAC Macerich
$8.14 /

+0.53 (+6.97%)

DGLY Digital Ally
$3.35 /

+0.12 (+3.72%)

CEQP Crestwood Equity
$15.58 /

+0.625 (+4.18%)

BPY Brookfield Property
$11.55 /

+0.23 (+2.03%)

BLNK Blink Charging
$11.35 /

+0.82 (+7.79%)

BLDP Ballard Power
$15.02 /

-0.3 (-1.96%)

AYRO AYRO
$4.46 /

-0.115 (-2.51%)

Hot Stocks
Lipocine announces peer reviewed publication of LPCN Liver Fat Study » 08:05
08/03/20
08/03
08:05
08/03/20
08:05
LPCN

Lipocine

$1.55 /

+0.05 (+3.33%)

Lipocine announced the…

Lipocine announced the peer reviewed publication of LPCN 144 Liver Fat Study results in Hepatology Communications. LPCN 1144 is an oral prodrug of bioidentical testosterone. The study aims were: to determine the prevalence of NAFLD within a population of hypogonadal males and the relationship of circulating testosterone levels with the presence and severity of NAFLD, to evaluate the impact of LPCN 1144 on hepatic steatosis and markers of liver injury in hypogonadal men, and to assess the safety and tolerability of LPCN 1144 in this population. The company expects results from its on-going Phase 2a LiFT clinical study in biopsy confirmed NASH subjects by the end of 2020.

ShowHide Related Items >><<
LPCN Lipocine
$1.55 /

+0.05 (+3.33%)

LPCN Lipocine
$1.55 /

+0.05 (+3.33%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
  • 14
    Nov
Hot Stocks
Lipocine says derivative lawsuit dismissed » 08:03
07/31/20
07/31
08:03
07/31/20
08:03
LPCN

Lipocine

$1.50 /

+ (+0.00%)

Lipocine announced that…

Lipocine announced that Wajda v. Patel, et al., Case: 2019-0122-JTL, a putative shareholder derivative action, was dismissed by Vice Chancellor Laster of the Chancery Court of Delaware. The derivative action was filed on February 15, 2019 against the Lipocine Inc.'s board of directors, and Lipocine as a nominal defendant. The Court granted Lipocine's motion to dismiss, holding that the plaintiff had failed to allege demand futility as required under Delaware Chancery Rule 23.1.

ShowHide Related Items >><<
LPCN Lipocine
$1.50 /

+ (+0.00%)

LPCN Lipocine
$1.50 /

+ (+0.00%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
  • 14
    Nov
Hot Stocks
Lipocine regains Nasdaq compliance » 08:14
07/13/20
07/13
08:14
07/13/20
08:14
LPCN

Lipocine

$1.33 /

-0.01 (-0.75%)

Lipocine announced that…

Lipocine announced that it has received a letter from The Nasdaq Stock Market on July 9 indicating that Lipocine has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2).

ShowHide Related Items >><<
LPCN Lipocine
$1.33 /

-0.01 (-0.75%)

LPCN Lipocine
$1.33 /

-0.01 (-0.75%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
  • 14
    Nov
Over a month ago
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 13:25
06/15/20
06/15
13:25
06/15/20
13:25
LPCN

Lipocine

$0.91 /

+0.0385 (+4.43%)

Biotech Analyst Rahimi…

Biotech Analyst Rahimi discusses why the oral testosterone TLANDO could represent a game changer for treating hypogonadism in males on an Analyst/Industry conference call to be held on June 15 at 2 pm.

ShowHide Related Items >><<
LPCN Lipocine
$0.91 /

+0.0385 (+4.43%)

LPCN Lipocine
$0.91 /

+0.0385 (+4.43%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 04:55
06/15/20
06/15
04:55
06/15/20
04:55
LPCN

Lipocine

$0.87 /

-0.0413 (-4.53%)

Biotech Analyst Rahimi…

Biotech Analyst Rahimi discusses why the oral testosterone TLANDO could represent a game changer for treating hypogonadism in males on an Analyst/Industry conference call to be held on June 15 at 2 pm.

ShowHide Related Items >><<
LPCN Lipocine
$0.87 /

-0.0413 (-4.53%)

LPCN Lipocine
$0.87 /

-0.0413 (-4.53%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 13:59
06/11/20
06/11
13:59
06/11/20
13:59
LPCN

Lipocine

$0.90 /

-0.0751 (-7.74%)

Biotech Analyst Rahimi…

Biotech Analyst Rahimi discusses why the oral testosterone TLANDO could represent a game changer for treating hypogonadism in males on an Analyst/Industry conference call to be held on June 15 at 2 pm.

ShowHide Related Items >><<
LPCN Lipocine
$0.90 /

-0.0751 (-7.74%)

LPCN Lipocine
$0.90 /

-0.0751 (-7.74%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
Recommendations
Lipocine price target raised to $3 from $2 at H.C. Wainwright » 06:56
05/27/20
05/27
06:56
05/27/20
06:56
LPCN

Lipocine

$0.96 /

-0.0311 (-3.15%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat raised the firm's price target on Lipocine to $3 from $2 and keeps a Buy rating on the shares. The analyst revived the prospects of Tlando, an oral testosterone replacement therapy, after recent developments.

ShowHide Related Items >><<
LPCN Lipocine
$0.96 /

-0.0311 (-3.15%)

LPCN Lipocine
$0.96 /

-0.0311 (-3.15%)

11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg
Over a quarter ago
Hot Stocks
Lipocine's LPCN improves NASH, hepatic fibrosis features in pre-clinical study » 08:09
05/13/20
05/13
08:09
05/13/20
08:09
LPCN

Lipocine

$0.73 /

+0.015 (+2.10%)

Lipocine announced the…

Lipocine announced the results of a pre-clinical study of LPCN 1144, an oral prodrug of bioidentical testosterone. The pharmacological effect of LPCN 1144 was investigated in a non-genomic, five arm, 12-week high fat diet - HFD - -induced, rabbit animal model of NASH and hepatic fibrosis. In the pre-clinical study, the HFD induced histological NASH features with fibrosis, altered key biomarkers, and lowered serum testosterone levels. Histological and biomarker analyses also demonstrate that LPCN 1144 improved HFD-induced NASH features and hepatic fibrosis. LPCN 1144 treatment reduced HFD-induced visceral fat increase and insulin resistance. Lipocine plans to present the results at an upcoming scientific conference. LPCN 1144 is currently being studied in the LiFT Phase 2 paired biopsy clinical study in patients with confirmed non-cirrhotic NASH.

ShowHide Related Items >><<
LPCN Lipocine
$0.73 /

+0.015 (+2.10%)

LPCN Lipocine
$0.73 /

+0.015 (+2.10%)

11/11/19 H.C. Wainwright
Lipocine price target lowered to $2 from $5 at H.C. Wainwright
11/11/19 Ladenburg
Lipocine downgraded to Neutral from Buy at Ladenburg

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.